These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 29976546)

  • 1. Persistent neutrophilic scarring alopecia triggered by anti-TNF blockade for Crohn's disease.
    Amschler K; Mc Broekaert S; Mohr J; Schön MP; Mößner R
    Eur J Dermatol; 2018 Jun; 28(3):403-405. PubMed ID: 29976546
    [No Abstract]   [Full Text] [Related]  

  • 2. Stricturing and Fistulizing Crohn's Disease Is Associated with Anti-tumor Necrosis Factor-Induced Psoriasis in Patients with Inflammatory Bowel Disease.
    Weizman AV; Sharma R; Afzal NM; Xu W; Walsh S; Stempak JM; Nguyen GC; Croitoru K; Steinhart AH; Silverberg MS
    Dig Dis Sci; 2018 Sep; 63(9):2430-2438. PubMed ID: 29736839
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Case of psoriasiform and pustular eruptions in addition to alopecia as a paradoxical reaction induced by infliximab.
    Shimokata M; Namiki T; Tokoro S; Ugajin T; Miura K; Yokozeki H
    J Dermatol; 2018 Dec; 45(12):e331-e333. PubMed ID: 29855072
    [No Abstract]   [Full Text] [Related]  

  • 4. Tumor necrosis factor-induced alopecia: alternative pathology and therapy.
    Udkoff J; Cohen PR
    Dermatol Online J; 2017 Jun; 23(6):. PubMed ID: 28633753
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adalimumab-induced psoriatic alopecia/alopecia areata-like reaction in a patient with Crohn's disease.
    Toda-Brito H; Lopes L; Soares-Almeida L; Filipe P
    Dermatol Online J; 2015 Nov; 21(11):. PubMed ID: 26632930
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Solitary facial cutaneous chronic inflammatory lesions induced by anti-tumour necrosis factor-α antagonist.
    Haro-Gabaldón V; Ruiz Molina I; Haro-González-Vico V; Solís García E
    Clin Exp Dermatol; 2019 Jan; 44(1):80-82. PubMed ID: 30255515
    [No Abstract]   [Full Text] [Related]  

  • 7. Alopecia secondary to anti-tumor necrosis factor-alpha therapy.
    Ribeiro LB; Rego JC; Estrada BD; Bastos PR; Piñeiro Maceira JM; Sodré CT
    An Bras Dermatol; 2015; 90(2):232-5. PubMed ID: 25830994
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Infliximab and adalimumab-induced psoriasis in Crohn's disease: a paradoxical side effect.
    Iborra M; Beltrán B; Bastida G; Aguas M; Nos P
    J Crohns Colitis; 2011 Apr; 5(2):157-61. PubMed ID: 21453886
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Paradoxical psoriasiform reactions to antitumour necrosis factor-α drugs in hidradenitis suppurativa.
    Dequidt L; Cogrel O; Guillet S; Milpied B; Darrigade AS; Beylot-Barry M; Pham-Ledard A
    Br J Dermatol; 2018 Jan; 178(1):281-283. PubMed ID: 28444990
    [No Abstract]   [Full Text] [Related]  

  • 10. Development of psoriasis scalp with alopecia during treatment of Crohn's disease with infliximab and rapid response to both diseases to ustekinumab.
    Andrisani G; Marzo M; Celleno L; Guidi L; Papa A; Gasbarrini A; Armuzzi A
    Eur Rev Med Pharmacol Sci; 2013 Oct; 17(20):2831-6. PubMed ID: 24174369
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adalimumab-induced psoriasis in a patient with Crohn's disease.
    Korkmaz U; Duman AE; Dindar G; Yilmaz H; Dursun IH; Celebi A; Senturk O; Hulagu S
    Indian J Gastroenterol; 2013 Mar; 32(2):135-6. PubMed ID: 23151897
    [No Abstract]   [Full Text] [Related]  

  • 12. [Ustekinumab in a patient with Crohn's disease and anti-TNF-α-induced psoriasis].
    Sansó Sureda A; Rocamora Durán V; Sapiña Camaró A; Royo Escosa V; Bosque López MJ
    Gastroenterol Hepatol; 2011 Oct; 34(8):546-50. PubMed ID: 21665330
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adalimumab-induced scalp psoriasis with severe alopecia.
    Özkur E; Altunay İK; Leblebici C; Topkarcı Z; Erdem Y
    Dermatol Ther; 2019 Sep; 32(5):e13033. PubMed ID: 31350777
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Psoriatic Alopecia in a Patient With Crohn Disease: An Uncommon Manifestation of Tumor Necrosis Factor α Inhibitors.
    Carrasquillo OY; Pabón-Cartagena G; Barrera-Llaurador J; Colón-Fontanez F; Martín-García RF
    Cutis; 2021 Apr; 107(4):E48-E55. PubMed ID: 34096864
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Development of diffuse alopecia with psoriasis-like eruptions during administration of infliximab for Crohn's disease.
    Kawashima K; Ishihara S; Yamamoto A; Ohno Y; Fukuda K; Onishi K; Kinoshita Y
    Inflamm Bowel Dis; 2013 Mar; 19(3):E33-4. PubMed ID: 22508420
    [No Abstract]   [Full Text] [Related]  

  • 16. [Flexural psoriasis induced by infliximab and adalimumab in a patient with Crohn's disease].
    Avila Alvarez A; García-Alonso L; Solar Boga A; García-Silva J
    An Pediatr (Barc); 2009 Mar; 70(3):278-81. PubMed ID: 19409245
    [TBL] [Abstract][Full Text] [Related]  

  • 17. TNF inhibitor induced alopecia: an unusual form of psoriasiform alopecia that breaks the Renbök mold.
    Craddock LN; Cooley DM; Endo JO; Longley BJ; Caldera F
    Dermatol Online J; 2017 Mar; 23(3):. PubMed ID: 28329519
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Psoriasis and Psoriasiform Eruptions in Pediatric Patients with Inflammatory Bowel Disease Treated with Anti-Tumor Necrosis Factor Alpha Agents.
    Eickstaedt JB; Killpack L; Tung J; Davis D; Hand JL; Tollefson MM
    Pediatr Dermatol; 2017 May; 34(3):253-260. PubMed ID: 28211161
    [TBL] [Abstract][Full Text] [Related]  

  • 19. SAFETY PROFILE OF ANTI-TNF THERAPY IN CROHN'S DISEASE MANAGEMENT: A BRAZILIAN SINGLE-CENTER DIRECT RETROSPECTIVE COMPARISON BETWEEN INFLIXIMAB AND ADALIMUMAB.
    Bau M; Zacharias P; Ribeiro DA; Boaron L; Steckert Filho A; Kotze PG
    Arq Gastroenterol; 2017 Dec; 54(4):328-332. PubMed ID: 28954043
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anti-tumour necrosis factor alpha therapy and increased risk of de novo psoriasis: is it really a paradoxical side effect?
    Joyau C; Veyrac G; Dixneuf V; Jolliet P
    Clin Exp Rheumatol; 2012; 30(5):700-6. PubMed ID: 22935567
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.